

## PCV (pneumococcal conjugate vaccine) Prevnar® Schedules for Children Quick Reference Guide #104 Revised 2-9-12

### Routine PCV Schedule using PCV13

All children should receive a 3 dose primary series and a booster dose if vaccination is begun at ≤6 months of age.

Age	2 months	4 months	6 months	12 to 15 months
Dose Number	1 <sup>st</sup> dose	2 <sup>nd</sup> dose	3 <sup>rd</sup> dose	Booster dose

### Schedule for Transition from PCV7 to PCV13

Infants and children aged <24 months who have received one or more doses of PCV7 should complete the PCV series with PCV13. A single supplemental dose of PCV13 is recommended for all children 14 through 59 months of age who have received 4 doses of PCV7 or another age-appropriate complete PCV7 schedule ≥8 weeks after most recent dose.

Infant Series			Booster dose	Supplemental PCV13 dose
2 months	4 months	6 months	12 to 15 months	14-59 months*
PCV7	PCV7	PCV7	PCV7	PCV13
PCV7	PCV13	PCV13	PCV13	none
PCV7	PCV7	PCV13	PCV13	none
PCV7	PCV7	PCV7	PCV13	none

\*For children with underlying medical conditions that are indications for pneumococcal vaccination, a supplemental dose of PCV13 is recommended through age 71 months. See the back of this document for a list of children with these conditions.

### PCV13 Schedule for Children Who Start Late

If a child **starts** the PCV series at ≥7 months of age the child will not need as many doses to complete the series.

Age at First Dose	Number of Doses	Booster Dose
7-11 months	2 doses, 2 months apart	1 dose at 12-15 months
12-23 months	2 doses, 2 months apart	None
24-59 months (2 through 4 years) – healthy children	1 dose	None

### PCV13 Schedule for Children Who Start the Series on Time and Then Fall Behind (Lapsed Schedule)

Child's Current Age	Number of Previous Doses	Doses Needed to Complete the Series	
2-6 months	1 dose	2 doses 2 months apart and a booster at 12-15 months of age	
	2 doses	1 dose 2 months after the last dose and a booster at 12-15 months of age	
7-11 months	1 or 2 doses	1 dose now and a booster at 12-15 months of age at least 2 months later	
12-23 months	1 dose before age 12 months	2 doses, 2 months apart	
	1 dose at 12 months of age or older	1 dose at least 2 months after the previous dose	
	2 or 3 doses before age 12 months	1 dose at least 2 months after the previous dose	
24-59 months (2 through 4 years)	1 to 3 doses before age 12 months and no doses after 12 months	1 dose*	*2 doses, 2 months apart, are recommended for children 24-71 months (2 through 5 years) of age with underlying medical conditions that are indications for pneumococcal vaccination. See the back of this document for a list of children with these conditions.
	1 dose at age 12-23 months		

**Routine use of PCV (PCV7 or PCV13) is not recommended for healthy children 5 years of age and older even if the child never received any PCV and it is not required for child care attendance for children 5 years of age and older in Oklahoma. PCV is required for children younger than 5 years of age attending child care in Oklahoma.**

**Children ages 24-71 months with certain underlying medical conditions may need additional doses of PCV not listed in the tables above. Please refer to the table below for more information. These additional doses are not required for child care attendance in Oklahoma.**

**Underlying medical conditions that are indications for pneumococcal vaccination among children, by risk group**

Risk Group	Condition
Immunocompetent children	Chronic heart disease, particularly cyanotic congenital heart disease and cardiac failure Chronic lung disease, including asthma if treated with high-dose oral corticosteroid therapy Diabetes mellitus Cerebrospinal fluid leaks Cochlear implant
Children with functional or anatomic asplenia	Sickle cell disease and other hemoglobinopathies Congenital or acquired asplenia
Children with immunocompromising conditions	HIV infection Chronic renal failure and nephrotic syndrome Disease associated with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemia, lymphomas and Hodgkin disease; or solid organ transplantation Congenital immunodeficiency*

\*Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease).

Children 24-71 months of age with chronic or immunocompromising conditions listed above who have not previously received any PCV vaccine need 2 doses of PCV13 given 2 months apart or at least a minimum interval of 8 weeks between doses.

**Children 6 through 18 years of Age with Certain High-Risk Conditions**

A single dose of PCV13 may be administered to children 6 through 18 years who have not received PCV13 previously and are at increased risk for invasive pneumococcal disease because of anatomic or functional asplenia, including sickle cell disease, immunocompromising conditions such as HIV infection, cochlear implant, or cerebrospinal fluid leaks, regardless of whether or not they have previously received PCV7 or PPSV23 (pneumococcal polysaccharide vaccine, 23 valent).

**Administration of PPSV23 after PCV7 or PCV13 among Children 2-18 years of Age Who Are at Increased Risk for Pneumococcal Disease**

**Children ≥2 years of age with underlying medical conditions\* should receive PPSV23 after completing all recommended doses of PCV7/PCV13.**

Group	Schedule for PPSV23	Revaccination with PPSV23
Children who are immunocompromised, have sickle cell disease, or functional or anatomic asplenia	1 dose of PPSV23 at ≥2 years of age & ≥8 weeks after last dose of PCV13	A single revaccination 5 years after first dose of PPSV23
Immunocompetent children with chronic illness*	1 dose of PPSV23 at ≥2 years of age & ≥8 weeks after last dose of PCV13	Not recommended

\* Chronic heart disease, chronic lung disease, diabetes mellitus, cerebrospinal fluid leaks, or cochlear implant.

Routine use of PPSV23 after PCV7 or PCV13 is not recommended for American Indian/Alaska Native children ≥2 years of age without underlying medical conditions. In special situations use of PPSV23 after PCV7 or PCV13 may be recommended for this population when risk for disease is increased. This represents a change from the previously published ACIP recommendations. This changed with the publication of new ACIP recommendations for PCV and PPSV on Dec. 10, 2010, *MMWR* Vol. 59 No. RR-11.

For more information on the use of PCV please consult the Advisory Committee on Immunization Practices (ACIP) recommendations, which may be found at: <http://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf> or call the Immunization Service at 405-271-4073 or 1-800-234-6196 or visit our website at <http://imm.health.ok.gov>.